Technical Analysis for STRO - Sutro Biopharma, Inc.

Grade Last Price % Change Price Change
F 3.91 -4.87% -0.20
STRO closed down 4.87 percent on Monday, March 18, 2024, on 1.16 times normal volume. The stock fell below its 200 day moving average, damaging its long-term outlook by crossing under that critical trendline. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
Earnings due: Mar 28
*** please verify all earnings dates ***
0 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Down

Date Alert Name Type % Chg
Fell Below 200 DMA Bearish 0.00%
180 Bearish Setup Bearish Swing Setup 0.00%
Lower Bollinger Band Walk Weakness 0.00%
Below Lower BB Weakness 0.00%
Lower Bollinger Band Touch Weakness 0.00%
Oversold Stochastic Weakness 0.00%
Crossed Above 200 DMA Bullish -4.87%
Stochastic Buy Signal Bullish -4.87%
Lower Bollinger Band Touch Weakness -4.87%
Oversold Stochastic Weakness -4.87%

   Recent Intraday Alerts

Alert Time
Possible NR7 about 8 hours ago
60 Minute Opening Range Breakdown about 9 hours ago
Down 5% about 9 hours ago
Fell Below Previous Day's Low about 9 hours ago
Down 3% about 12 hours ago

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Sutro Biopharma, Inc. Description

Sutro Biopharma, Inc. operates as clinical stage drug discovery, development, and manufacturing company. It focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis platform, XpressCF. The company's product candidates include STRO-001, an antibody-drug conjugate (ADC) directed against the cancer target CD74 for multiple myeloma and non-Hodgkin lymphoma; and STRO-002, an ADC directed against folate receptor-alpha for patients with ovarian and endometrial cancers. It has collaboration and license agreement with Celgene Corporation to discover and develop bispecific antibodies and/or ADCs focused primarily on the field of immuno-oncology. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Cancer Clinical Medicine Biology Immunology Antibodies Cancer Treatment Drug Discovery Lymphoma Antineoplastic Drugs Multiple Myeloma Autoimmune Disorders Immune Disorders Endometrial Cancer Immunogen Therapeutics For Cancer Hodgkin Lymphoma Milatuzumab Non Hodgkin Lymphoma Ovarian And Endometrial Cancers

Is STRO a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 6.105
52 Week Low 2.005
Average Volume 840,132
200-Day Moving Average 4.10
50-Day Moving Average 4.48
20-Day Moving Average 4.62
10-Day Moving Average 4.42
Average True Range 0.34
RSI (14) 37.89
ADX 16.31
+DI 18.08
-DI 26.52
Chandelier Exit (Long, 3 ATRs) 4.47
Chandelier Exit (Short, 3 ATRs) 4.89
Upper Bollinger Bands 5.28
Lower Bollinger Band 3.96
Percent B (%b) -0.04
BandWidth 28.52
MACD Line -0.11
MACD Signal Line 0.00
MACD Histogram -0.1082
Fundamentals Value
Market Cap 238.33 Million
Num Shares 61 Million
EPS -2.91
Price-to-Earnings (P/E) Ratio -1.34
Price-to-Sales 5.98
Price-to-Book 2.54
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 4.23
Resistance 3 (R3) 4.25 4.17 4.17
Resistance 2 (R2) 4.17 4.09 4.16 4.15
Resistance 1 (R1) 4.04 4.04 4.00 4.02 4.14
Pivot Point 3.96 3.96 3.94 3.95 3.96
Support 1 (S1) 3.83 3.88 3.79 3.81 3.68
Support 2 (S2) 3.75 3.83 3.74 3.67
Support 3 (S3) 3.62 3.75 3.65
Support 4 (S4) 3.60